Generic competition to Prograf (tacrolimus) in the US continued to weigh on Astellas in the fiscal first quarter ended 30 June, although contributions from US acquisition OSI and newer products offset the decline.
Generic competition to Prograf (tacrolimus) in the US continued to weigh on Astellas in the fiscal first quarter ended 30 June, although contributions from US acquisition OSI and newer products offset the decline.
Sales of the immunosuppressant in the Americas slumped by 21% to $97 million, below the firm's internal forecast, with generics...
Months after terminating obesity candidate danuglipron, Pfizer is placing a hefty bet on Metsera and what it calls its highly differentiated incretin/amylin analog candidates.
Zovaglutide tied Amgen’s MariTide in weight reduction at Week 24 in a Phase II study, but with a potentially better safety profile. However, efficacy versus existing once-weekly drugs is a remaining question.
A small subgroup study in Novo Nordisk’s STEP UP trial used MRI to pinpoint where patients are losing lean mass. It suggests Wegovy patients do not lose muscle strength, but other companies are investigating muscle-preserving therapies.
About four months after GSK paid $1.2bn up front for another FGF21 analog in MASH, Roche looks to buy 89bio, adding Phase III pegozafermin to its growing cardiometabolic pipeline.
The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.
Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.
India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.
